Portuguese API and intermediates manufacturer Hovione has appointed Conrad Winters as director of Drug Product Development.
Winters was previously with Merck in the US and Canada and most recently with Xenon Pharmaceuticals, where he held the position of senior director, Compound Properties Group.
‘We are very pleased to welcome Dr Winters to Hovione. His experience in particle engineering, solubilisation, drug product development, scale up and commercialisation will enable us to solve our customers' most challenging problems,’ said Thomas Eisele, Hovione’s vp of Corporate Research & Development.
Winters has 18 years’ experience in the pharmaceutical industry with expertise in managing the development of compounds from lead candidate optimisation through to NDA submission and commercialisation.
